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A b s t r a c t  
The solid dispersions of indomethacin with hydrophilic polymers were prepared by lyophilization. The 
polymers used in the investigation were HPMC, PVP K30, CBR and PLF 127. The solubility and 
dissolution of indomethacin from prepared lyophilized solid dispersions were investigated in 0.1 N 
HCl, purified water and USP-NF dissolution media.  Out of fifteen lyophilized formulations from F1 to 
F15, five formulations F2, F5, F8, F12 and F14 showed highest solubility in purified water. 
Formulation F2, F8 failed to comply with the USP-NF dissolution test for indomethacin capsules. 
Formulation F14 showed maximum dissolution in the respective dissolution media within 60 min.  
Sustained drug release was observed for 6 h with formulations F2 and F8 in USP-NF media. The 
formulations F2, F5, F8, F12 and F14 were characterized by modulated DSC and FT-IR 
spectroscopy. Some Formulations on stability testing were found physico-chemically stable at 
accelerated temperature conditions. 
Keywords: lyophilization, indomethacin, Solid dispersions, Dissolution, Stability. 
Introduction 
 
The solubility and dissolution of aqueous insoluble drugs has been 
improved by solid dispersion technique, using hydrophilic polymer 
carriers in which the insoluble drug is dispersed in amorphous state 
[1]. The solid dispersion technique is highly accepted in 
pharmaceutical industry in the formulation of water insoluble drugs 
for increasing their oral absorption [2-5]. The mechanism involved in 
the solubility improvement, is the ability of hydrophilic polymer 
carrier to prevent the drug precipitation in the aqueous environment 
of GI tract [6-10]. 
Examples of FDA approved solid dispersions based drugs include 
Itraconazole, Tacrolimus, lopinavir, Etravirine, Everolimus, 
Telaprevir, Troglitazone, Nifedipine, verapamil [2-11]. 
Solvent evaporation and hot melting methods are utilized mainly in 
the preparation of solid dispersions [2]. Major disadvantages of hot 
melting method is that the method can only be applied to thermos 
table, low melting point drugs and carriers; the miscibility and 
compatibility of  polymer-drug physical mixture at high temperature; 
prolong time required for cooling of the melted physical mixtures 
results in recrystallization of amorphous drug [2,3]. Lyophilisation is 
an industrially applicable method alternate to hot melt method; have 
advantages of being applicable to thermo-sensitive drugs; as the 
substances are exposed to minimum heating in the process and 
there is minimum risk of phase separation [12-14]. The major 
problem associated with amorphous solid dispersions is the 
thermodynamic instability leading to recrystallization of amorphously 
dispersed drug. Extensive research has been going on to find the 
ways for prevention of recrystallization of amorphous drugs in solid 
dispersions [15-20]. Polymers such as Polyvinylpyrrolidone, 
hydroxypropylmethyl cellulose acetate succinate, Eudragit EPO, 
Polyvinylpyrrolidone–vinyl acetate copolymer prevent the 
precipitation and crystallization of amorphous drugs in solution [6, 8, 
15-20]. The stability of drugs in solid dispersions has been found 
improved by addition of surface active agents [20]. 
Surfactants acts by preventing recrystallization of drugs from 
amorphous state [20]. In the aqueous dissolution media interaction 
between surfactant and polymer carrier results in extremely stable 
aqueous dispersions of amorphous colloidal particles [21]. 
Indomethacin (IMC)a non-steroidal anti-inflammatory drug used in 
the treatment of arthritis; has been selected because it is water 
insoluble (0.937mg/L), highly lipophilic (log P value 4.27), low 
solubility and high permeability; a BCS class II drug 
(http://www.drugbank.ca/drugs/DB00328#spectra). 
Indomethacin is readily soluble but very unstable in alkaline 
solutions with rapid decomposition [22-25]. Several Solid Dispersion 
systems of water insoluble indomethacin with hydrophilic carriers 
have been reported in the literature but it has not been studied with 
system based on carbomer hydrogel, prepared by freeze drying [23-
28]. The amorphous solid dispersions with low degree of 
recrystallization have been reported with 2-hydroxyethyl 
methacrylate (PHEMA) [29-30].  
Carbomers (CBR); the hydrophilic polyacrylic acid derivatives have 
been employed in the preparation of gels, oral solid dosage forms 
[31-32], solid dispersions [33,34]. 
PVPK30 and HPMC 4000cps are widely accepted excipients for 
solid dosage forms; used in the preparation and stabilization of solid 
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dispersions [35-39]. Pluronic acid F 127(PLF 127) was investigated 
as carrier in the preparation of solid dispersions for its surfactant 
properties [40, 41] 
The selection of hydrophilic carrier in the preparation of solid 
dispersions is based on number of factors such as method of 
preparation; for example PVP, HPMC and carbomers are not 
suitable carriers for hot melt method as these polymers are 
completely burn down at high temperature, hence suitable to be 
used in solvent evaporation method [42]. The other factor involved 
is the determination of drug solubility in the aqueous solution of the 
polymer [43]. Since it is difficult to achieve drug- polymer solubility 
equilibrium in the highly viscous environment of polymer solution, 
the exact solubility of drug in polymer solution cannot be calculated 
[43, 44]. 
The present study has been done with objectives; preparation and 
characterization of amorphous indomethacin solid dispersions 
(LSDs) with carbomer 940P, Polyvinylpyrrolidone K30, 
Hydroxypropylmethyl cellulose 4000cps and Pluronic F127 as 
hydrophilic carriers by lyophilisation using hydro-alcoholic vehicle. 
Selection of LSDs formulations to be reformulated in non- alcoholic 
aqueous vehicle for further investigations. 
 
Materials and Methods 
 
Indomethacin [IMC] was purchased from Alfa Aesar, GmbH & Co 
KG, Germany. Hydroxypropylmethyl cellulose 4000cps (HPMC), 
Polyvinylpyrrolidone K30(PVP) and carbomer 940P(CBR), lactose 
were purchased from UFC Biotechnology, Amherst, USA. Pluronic 
F127 (PLF 127), Indomethacin RS, Potassium phosphate 
monobasic and ethanol (99.9% HPLC grade) were purchased from 
sigma aldrich USA. All other chemicals used in the experimental 
study were of analytical grade. 
Preparation of Indomethacin- Polymer aqueous solution 
 
IMC-polymer aqueous solution in the ratio of 1:1(1part IMC and 
1Part PVP) was prepared as follows. 1g of polymer was dispersed 
in 50 ml of purified water (RO water) over the period of 15 minutes 
with constant stirring using magnetic stirrer. Solution of IMC in 
ethanol (1g/10ml) was prepared and added slowly drop wise in to 
the solution of PVP maintained under constant stirring conditions 
over a period of 15 minutes. Similarly drug polymer mixtures in 
different ratios have been prepared with CBR, PVP K30, HPMC 
4000cps and PLF 127. 
Lyophilization 
 
The IMC-Polymer aqueous solutions prepared were transferred in to 
open clear glass bottles of 60ml, frozen at -30oC for 24h. Solvent 
was removed by two stage lyophilisation (Freeze drier Christ Beta 
2-8 LD Plus, Martin Christ Germany).first stage the main drying was 
done at condenser temperature -20oC, vacuum 1 mbar for 12 hr. At 
second stage which followed first stage automatically, the final 
drying was done at condenser temperature -31oC, vacuum 0.34 
mbar for 12hr.  The LSDs were further kept in vacuum desiccator for 
12 h and were stored in screw capped clear glass bottles sealed 
with paraffin film. 
Drug content determination 
 
Accurately weighed LSDs equivalent to 50mg of IMC was dispersed 
in 10ml of purified water and it is gently shaken for 15 minutes. 50 
ml methyl alcohol was added and the solution was shaken well. 
Sufficient methanol was added to produce 100ml. filter the solution, 
to the 5ml of filtrate, a mixture of equal volume of methanol and 
phosphate buffer pH 7.2 was added to produce 100ml 
(0.025mg/ml). The optical density (AT) of the solution was 
determined at 320nm by using Evolution 60S UV-visible 
spectrophotometer[45].The absorbance (As) of indomethacin RS 
standard solution (0.025mg/ml) prepared with same procedure as 
described was measured. The content of IMC in LSDs was 
calculated with following equation. 
           =
  
  
	 	     
     =         	       	  	   	  	  (50  ) 
Solubility profile of lyophilized solid dispersions 
 
 Solubility of LSDs was determined in purified water and simulated 
gastric fluid without enzymes (solution of 0.2%w/v NaCl and 0.7% 
HCl in purified water). An excess amount of LSDs was added to 25 
ml of purified water in glass bottles (screw capped capacity 50 ml). 
The dispersion was equilibrated by shaking in a warm bath at 
37oC±0.5oC for 48 h. After 48h, the mixture was centrifuged and the 
supernatant was diluted to 100ml with the respective media and 
absorbance was measured at 320nm spectrophotometrically [45]. 
The concentration of drug was determined from standard calibration 
curve of standard indomethacin; prepared with concentration range 
10µg/ml to 50µg/ml. A phase diagram of indomethacin solubility 
(mcg/ml) vs polymer (%w/w) was constructed; compared with the 
solubility of pure crystalline IMC RS.  
 
In-vitro Dissolution Testing  
 
Dissolution investigations were performed on filled capsules 
containing the LSDs equivalent to 50mg of IMC. The testing was 
done with USP basket apparatus Type I; Erweka Germany. The 
dissolution media used was 750ml of USP30-NF25 media for IMC 
capsules (pH7.2), paddle rotation speed 50rpm; maintained at 
37oC±0.5. The test was performed for 1 h; 10ml sample was 
withdrawn, substituted with pre-warmed media, at 20minutes time 
interval, filtered, diluted to 50 ml with the dissolution media and the 
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absorbance of the solution was measured at 320nm. The 
percentage drug dissolved was calculated from Specific absorbance 
     
 %   of indomethacin RS (45).The dissolution testing was also 
done in 0.1N HCl and purified water as dissolution media. The test 
was done in duplicate and average value of the two was recorded.  
Differential scanning Calorimetry (DSC) 
 
Thermal behavior of IMC, LSDs were recorded by differential 
scanning calorimeter, Modulated DSC VI.1A was used with an 
argon purge at 45cc/min in order to determine the melting 
endotherm on set temperature and heat of fusion( H). Samples 
were heated at 10oC/min under nitrogen atmosphere in the 70-
250oC. The instrument was calibrated for temperature and enthalpy 
with indium. 
The ΔH of the pure crystalline drug, in LSDs was determined. The 
percent crystallinity of the drug in the LSDs was calculated using the 
following equation from heat of fusion [42, 43]: 
Percentage crystallinity = 100 x 
   
   	 	 
  
 
ΔHs, ΔHc are the enthalpy of LSDs and pure crystalline drug 
respectively. 
C is the amount of drug (weight fraction) in the LSDs.  
The pure drug was assumed as 100% crystalline.  
 
Fourier Transform Infrared Spectroscopic studies (FTIR) 
 
Spectrum of IMC, LSDs and hydrophilic polymers was recorded on 
Cary 630 FTIR spectrophotometer, Agilent Technologies. The IR 
determinations were carried out in the scanning range of 4000-
650cm-1[44-45]. 
 
Stability evaluation 
 
LSDs in sealed screw capped clear glass bottles were placed at 
45oC for 90 days in HERATHERM Incubator (Thermo scientific). At 
the interval of 30days, samples were evaluated for appearance, 
drug contents and dissolution rate. 
Results and Discussion 
 
Drug content Uniformity 
A UV spectrum of IMC prepared in Phosphate buffer pH 7.2 was 
presented in figure 1; indicated the λmax at 321nm. A standard 
calibration curve for IMC was prepared with concentration of drug 
10µg/ml to 70µg/ml in phosphate buffer pH 7.2, was represented in 
figure 1.1. The curve was found linear and the R2 = 0.997. 
 
Figure1: UV-Spectra of IMC in Phosphate Buffer pH 7.2 
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Figure 1.1: Standard calibration curve of indomethacin 
 
Fifteen LSD formulations of IMC with HPMC, PVP, CBR and PLF 
127 in different ratios were prepared and coded F1 to F15 (Table 1). 
The IMC content in all the formulations was found in the range of 
98% to 99%. All the formulations complied for USP-NF test for 
content uniformity. 
 
Table 1: LSDs formulations of Indomethacin with different polymers 
Code               Formulation Drug content (%± SD) 
F1  
IMC: HPMC 
1:1 99.21±0.37 
F2 1:1.5 99.30±0.23 
F3 1:2 98.41±0.45 
F4  
IMC: PVPK30 
1:1 98.40±0.35 
F5 1:1.5 98.45±0.39 
F6 1:2 99.30±0.42 
F7  
IMC: CBR 
1:1 98.87±0.28 
F8 1:1.5 98.92±0.32 
F9 1:2 99.21±0.29 
F10  
IMC:HPMC:PLF127 
1:1:0.2 98.55±0.39 
F11 1:1:0.4 98.78±0.19 
F12 1:1:0.6 99.21±0.22 
F13  
IMC:PVP:PLF127 
1:1:0.2 98.46±0.29 
F14 1:1:0.4 99.50±0.34 
F15 1:1:0.6 98.76±0.28 
Solubility of LSDs 
 
Figure 1(a) represents the solubility profile of LSDs in purified water. 
The concentration of IMC 29.13 mcg/ml was found with LSDs 
prepared with HPMC, formulation F1. 30.31 mcg/ml concentration of 
IMC was found with F2.The concentration of IMC 15.84 mcg/ml was 
found with LSD containing PVPK30 in drug to polymer ratio 1:1(F4), 
followed by F5,16.89 mcg/ml and F6,15.57 mcg/ml respectively. 
Lowest concentration of IMC 1.63mcg/ml was found in LSDs 
prepared with CBR (F7).  
 
CBR formulations showed slightly enhanced solubility of IMC in 
purified water. Formulations based on HPMC and PVP showed an 
increase in the solubility of IMC, 10 times and 5 times respectively 
in comparison to the CBR formulations. Maximum solubility of IMC 
was found with the formulations containing 150%w/w polymer. 
There is no further increase in solubility of IMC observed with 
further increase in the polymer weight in the formulations prepared 
with HPMC, PVP and CBR. 
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Figure 1(a): solubility of LSDs in purified water 
 
 
Figure 1(b): influence of plf 127 on solubility of lsds in purified water 
 
 
Figure 1(c): solubility of lsds in simulared gastric fluid 
 
HPMC, PVP based LSD formulations were prepared with PLF 127 
ranging from 20%w/w to 60% w/wcoded from F10 to F15. The figure 
1(b) represented the effect of addition PLF 127 on solubility of IMC 
from Formulation F1 to F6. The concentration of IMC in solution; 
40.05mcg/ml and 23.21mcg/ml was found with formulation F12 and 
F14 respectively. Addition of PLF 127 to the PVP K30 based 
formulation F4 results in the 50% increase in concentration of IMC 
in formulation F14. The solubility determinations carried out in SGF 
were represented in figure 1(c). The maximum concentration of IMC 
0.973mcg/ml, 3.34mcg/ml,0.449,5.97mcg/ml and 2.55mcg/ml was 
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found in SGF for formulation F2, F5, F8, F11 and F15.  These 
results indicated that concentration of IMC in solution from LSDs 
depended on the type of polymer used in the formulation. The 
highest drug concentration was observed with HPMC based 
formulations followed by PVPK30. There was least effect of CBR on 
the concentration of IMC. Drug solubility of IMC in purified water 
was found increased with the addition of PLF 127 in HPMC and 
PVPK30 formulations(F10 to F15) and was found depended on the 
amount of PLF127 in the formulation(figure 1b). F2, F5, F8, F12 and 
F14 formulations based on HPMC, PVPK30, CBR and PLF127 
showed maximum solubility of IMC within each group in purified 
water and were selected for further investigations. 
 
In-vitro Dissolution Testing  
 
Dissolution of Indomethacin RS 
 
The specific absorbance     
 %  of indomethacin solution (10mg/ml) 
at 320nm was reported 193(41). Mathematically the absorbance of 
0.0133mg/ml solution of indomethacin(  	) was calculated as 
follows: 
 
10
193
=
0.0133
  
  ;   	 = 0.256 
Experimentally; 50mg of indomethacin RS was accurately weighed 
and was dissolved in freshly prepared 750ml dissolution media as 
per USP30-NF25, composed of 1 part phosphate buffer pH 7.2 and 
4 part purified water. The media was stirred at 100rpm using 
magnetic stirrer. The temperature of the medium was maintained at 
37oC.  
10 ml of sample was withdrawn from the solution after 60 minutes 
and replaced with fresh dissolution medium maintained at same 
temperature, made up to 50ml with dissolution medium in a 50ml 
volumetric flask (0.0133mg/ml). The absorbance of the resulting 
solution was measured spectrophotometrically at 320nm. The 
experiment was carried out in triplicate and the average standard 
absorbance(  )was found 0.258.   was used to calculate the 
percentage drug dissolved at different time intervals in the 
dissolution experiments of LSDs as follows; 
 
%	   	          =
  
  
	 	100 
 
Where′  ′: absorbance of the test sample 
 
Dissolution of LSDs in USP-NF Media 
 
Figure 2(a) represents the dissolution profile of LSDs in USP-NF 
dissolution media. The percentage dissolved IMC at 20 minutes 
interval was found 27.73, 83.2, 12.0, 76.95, and 100.1 % for F2, F5, 
F8, F12 and F14 respectively. At 40 minutes time interval the 
percentage IMC dissolved was found 32.03, 98.43, 14.84, 85.54, 
and 100% for F2, F5, F8, F12 and F14 respectively. At 60 minutes 
time interval the percentage IMC dissolved was found 39.84, 99.21, 
15.23, 92.96, and 100.7% for F2, F5, F8, F12 and F14 respectively. 
The formulations were arranged in the increasing order for 
percentage dissolved at 60 minutes as F8<F2<F12<F5<F14. The 
USP-NF dissolution tolerance limit for indomethacin capsules stated 
as; not less than 80% of the labeled amount dissolved in 20 
minutes. Formulation F5, F12 and F14 complied at the USP-NF 
dissolution test tolerance limit for indomethacin capsules. 
 
 
Figure 2: In vitro dissolution profile of LSDs 
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Dissolution of LSDs in 0.1N HCl 
 
Figure 2(b) represents the dissolution profile of LSDs in 0.1N HCl. 
Dissolution of IMC capsule containing physical mixture of IMC and 
lactose equivalent to 50 mg of IMC was carried out that serve as 
reference capsule (RC) for comparison with LSDs. At 60 minutes 
time interval the percentage IMC dissolved was found 9.37, 13.28, 
14.84, 6.25, 16.01, and 16.79% for RC, F2, F5, F8, F12 and F14 
respectively. The formulations were arranged in the increasing order 
of percentage IMC dissolved as F8<RC<F2<F5<F12<F14 at 60 
minutes. 
 
Dissolution of LSDs in Purified water 
 
Figure 2(C) represents the dissolution profile of LSDs in purified 
water. Dissolution of 50mg of IMC capsule containing pure IMC was 
carried out that serve as reference (RC) for comparison with LSDs. 
Reference capsule contained 50mg of pure IMC mixed with 100mg 
of lactose. At 60 minutes time interval the percentage IMC dissolved 
was found 15.62, 26.95, 44.92, 18.28, 50.78, and 63.51% for RC, 
F2, F5, F8, F12 and F14 respectively. The formulations were 
arranged in the increasing order of percentage IMC dissolved as 
RC<F8<F2<F5<F12<F14 at 60 minutes. 
Figure 2(d) represents the comparative dissolution data of IMC 
formulations in USP-NF media, 0.1N HCl and purified water at 
t=20minutes.  Formulation F2 showed 27.73% IMC released in 
USP-NF, 16.01% in purified water, 11.71% in 0.1N HCl. In purified 
water, the drug released from F2 was 2 times higher than RC. 
Formulation F5 showed 83.2% IMC released in USP-NF media, 
32.03% in purified water, and 15.23% in 0.1N HCl. In purified water 
the drug released was 4.5 times higher than RC. Formulation F8 
showed 12.1% IMC released in USP-NF media, 4.68% in purified 
water, and 4.68% in 0.1N HCl. In purified water the drug released 
was similar to the RC. Formulation F12 showed 76.95% IMC 
released in USP-NF, 34.37% in purified water, 13.28% in 0.1N HCl. 
In purified water, the IMC released from F12 was 5 times higher 
than RC. Formulation F14 showed 100% IMC released in USP-NF, 
45.37% in purified water and 16.01% in 0.1N HCl. In purified water, 
the drug released was 7 times higher than RC. 
IMC, a week acidic drug pKa 4.5, readily dissolved in USP-NF 
dissolution media pH7.2.  The dissolution rate of IMC varied with the 
type of polymers. Maximum release of drug in all the three type of 
dissolution media that is USP-NF, 0.1 N HCl and purified water was 
found with F14 and F12 formulations based PLF 127 with PVP K30 
and HPMC followed by PVPK30 based F5 within 60 minutes. Very 
slow release of IMC was found with LSDs based on HPMC (F2) and 
CBR (F8).  
 
 
 
Figure 2(e): Sustained dissolution of F2&F8 in USP-NF 
 
The dissolution experiment for formulation F2 and F8 was 
conducted for 6 h in USP-NF dissolution media (figure 2e). The 
release of IMC from F2 and F8 was compared with marketed 
product (MP) as external standard and reference capsule containing 
50 mg of IMC as internal standard. At the end of 6h; 84% and 62% 
drug released was found with formulation F2 and F8 respectively. 
Sustained slow release of IMC in case of F2 and F8 formulations is 
due to the fact that the release of drug from hydrophilic matrixes of 
HPMC and CBR depended on the swelling behavior (gelation) 
which in turn influenced by the pH and temperature in case of CBR 
[49] and ionic strength of the dissolution media in case of HPMC 
[50]. The gel barrier is the major determining factor in the drug 
dissolution profile related to the time. The thicker and faster gel 
formation led to the slow release of drug (50).  
At the end of 60 minute dissolution test in USP-NF media for 
formulations F2, F5, F8, F12 and F14, the baskets of dissolution 
test apparatus were removed and pattern of gel formed was 
assessed by visual evaluation of bulkiness of the gel Figure 2F. In 
USP-NF dissolution media, gel formation with maximum bulkiness 
was observed in CBR based formulation F8 followed by HPMC 
based F2. 
The formulation F5, F12 and F14 had almost similar release profile 
indicated the inhibitory effect of PLF 127 on gel formation of HPMC 
in F12. PLF 127; a nonionic surfactant HLB value 29, improve the 
wettability and prevent the thickening of hydrogel in HPMC based 
F12. The PVPK30 based formulation F5 and F14 showed no sign of 
gel formation during dissolution process, complete dissolution was 
observed with few traces of residue was found in the dissolution 
basket after 60 minutes.  
The pattern of gel formation by LSDs in 0.1N HCl was found 
physically similar with that in purified water.  
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Figure 2:(f): Pattern of gel formation in dissolution media 
 
Differential scanning Calorimetry (DSC) 
 
IMC has demonstrated very much characterized endothermic 
pinnacle (Tm) at 161.03oC relating to the dissolving purpose of 
crystalline drug. There was complete absence of endothermic peak 
of INH was observed in all five formulations F2, F5, F8, F12 and 
F14. Wretchedness of melting point is not the same as IMC and 
individual polymer in this way affirming the arrangement of new 
stage. Bringing down of melting temperature focuses was because 
of the breaking of bonds, cluttered and non randomized structure of 
particle. It prompts bring down initiation vitality to achieve the 
dissolving focuses. The expansive, less sharp crests with lessening 
in dissolving purpose of IMC in strong scatterings indicates diminish 
in the slow disintegration of the medication in the polymer amid the 
DSC warming slope. The percentage crystallinity of IMC in each 
formulation was found 22.71, 19.06, 26.45, 11.75 and 18.42% 
respectively, endorsed the co-relation between the percentage 
crystallinity of IMC and the dissolution pattern of IMC from each 
formulation.  State of amorphousness of IMC demonstrated that it 
was molecularly scattered inside the carrier. 
Figure 3: DSC thermogram of IMC Solid Dispersions 
 
Fourier Transform Infrared Spectroscopic studies  
 
The structure of IMC was depicted in fig 3a. Figure 3b and 3C 
represented the FTIR spectrum of pure indomethacin, LSDs and 
Hydrophilic carriers respectively. Characteristic absorption peaks 
were appeared at frequencies 2967cm-1, 2928cm-1, 1713cm-1, 
1689cm-1, 1590cm-1, 1480 cm-1 and 1307cm-1.  Absorption peaks at 
2967 cm-1 and 2928 cm-1 were due to C-H stretching of methyl 
groups and aromatic rings. Peaks at 1713cm-1 and 1689cm-1 were 
due to the C=O stretching of two carbonyl groups pertaining to 
benzoyl and acidic group. Peaks due to C=C stretching of aromatic 
rings were found at 1590cm-1 and 1480 cm-1 .  Strong absorption 
peak at 1307cm-1was observed due C-N stretching.  No extra peaks 
was appeared in the spectra of prepared LSD formulations indicated 
no interactions between drug indomethacin and hydrophilic carrier. 
 
 
Figure 3(a): Structure of indomethacin 
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Figure3b: FTIR spectrum of LSDs. a) IMC, b) F2, c)F5,d) F8 e) F12 ,f) F14 
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Figure 3c: FTIR Spectrum Of Hydrophillic Polymers 
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Stability Evaluation 
 
Formulation F5, F12 and F14 complied with the USP30-NF25 
monograph dissolution test requirements for indomethacin 
capsules, were selected for stability studies for 3 month period.  All 
the three formulations were free flowing powder. The stability data 
for LSDs was presented in Table 2. The appearance of the test 
formulations was compared with the formulations kept at laboratory 
temperature.  There was no sign of any discoloration found in the 
formulations during the entire stability studies period.   Slightly 
melted mass formation was observed in formulation F12 and F14 
which resulted in formulation deposition (stickiness) at bottom of the 
bottle after one month of storage. This was due to the low melting 
point (56OC) of PLF 127. 
The amount of non-degraded drug present (% drug content) in 
LSDs was determined as per assay method described earlier. The 
formulations were found chemically stable with % drug content was 
not less than 98.37 in F5, 99.22 in F12 and 99.41 in F14 after 90 
days.  
The dissolution experiments was done in duplicate (n=2) as per 
USP-NF method described earlier. The amount of drug released 
after 20 minutes was determined 
 
Table 2: Stability Evaluation Data of LSDs 
Time(Days) 
 
Appearance 
 
% Drug content(n) 
Dissolution (t=20min) 
(% IMC Released) 
Media USP-NF* 
F5 F12 F14 F5 F12 F14 F5 F12 F14 
30       +    +   + 98.42 99.23 99.45 82.31 81.62 97.8 
60      +    +   + 98.36 99.21 99.43 83.72 82.17 94.57 
90      +    +   + 98.37 99.22 99.41 82.12 81.93 96.78 
+ ; no sign of discoloration                                                 n; an average of two determinations. 
 
Conclusion 
 
The solid dispersions of indomethacin prepared by lyophilization 
method showed enhancement in solubility and dissolution of 
indomethacin in purified water. Improvement in solubility and 
dissolution depended on the type, ratio and combination of 
hydrophilic polymer(s) used in the formulation.  There was no 
improvement in dissolution observed with CBR based F8 
formulation. Formulation F2, F5, F12 and F14 were found with 
enhanced dissolution by 2, 4.5, 5 and 7 times respectively than the 
pure drug indomethacin in purified water. Formulation F5, F12 and 
F14 comply the USP-NF dissolution test for indomethacin capsules. 
PLF 127 inhibited the gel formation of HPMC in USP-NF dissolution 
media. DSC confirmed the amorphous state of IMC in solid 
dispersions. There was no drug-polymer physico-chemical 
interaction found with FT-IR spectroscopic analysis.  Stability testing 
for three months indicated that the test formulations F12 and F14 
were physically unstable at accelerated temperature storage 
conditions. The formulations F2 and F5 were selected for further 
experimental studies 
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